{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:48:37Z","timestamp":1787237317792,"version":"build-2736575974"},"reference-count":13,"publisher":"Baskent University","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.6002\/ect.2022.0145","type":"journal-issue","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T09:13:36Z","timestamp":1666170816000},"source":"Crossref","is-referenced-by-count":4,"title":[],"prefix":"10.6002","volume":"22","member":"4021","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Sawada K, Fujishima N, Hirokawa M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol. 2008;142(4):505-514. doi:10.1111\/j.1365-2141.2008.07216.x","DOI":"10.1111\/j.1365-2141.2008.07216.x"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Brown KE, Young NS. Parvovirus B19 infection and hematopoiesis. Blood Rev. 1995;9(3):176-182. doi:10.1016\/0268-960x(95)90023-3","DOI":"10.1016\/0268-960X(95)90023-3"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Heegaard ED, Petersen BL, Heilmann CJ, Hornsleth A. Prevalence of parvovirus B19 and parvovirus V9 DNA and antibodies in paired bone marrow and serum samples from healthy individuals. J Clin Microbiol. 2002;40(3):933-936. doi:10.1128\/JCM.40.3.933-936.2002","DOI":"10.1128\/JCM.40.3.933-936.2002"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Brown KE, Young NS. Parvoviruses and bone marrow failure. Stem Cells. 1996;14(2):151-163. doi:10.1002\/stem.140151","DOI":"10.1002\/stem.140151"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Bell LM, Naides SJ, Stoffman P, Hodinka RL, Plotkin SA. Human parvovirus B19 infection among hospital staff members after contact with infected patients. N Engl J Med. 1989;321(8):485-491. doi:10.1056\/NEJM198908243210801","DOI":"10.1056\/NEJM198908243210801"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Waldman M, Kopp JB. Parvovirus-B19-associated complications in renal transplant recipients. Nat Clin Pract Nephrol. 2007;3(10):540-550. doi:10.1038\/ncpneph0609","DOI":"10.1038\/ncpneph0609"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Liefeldt L, Buhl M, Schweickert B, et al. Eradication of parvovirus B19 infection after renal transplantation requires reduction of immunosuppression and high-dose immunoglobulin therapy. Nephrol Dial Transplant. 2002;17(10):1840-1842. doi:10.1093\/ndt\/17.10.1840","DOI":"10.1093\/ndt\/17.10.1840"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Crabol Y, Terrier B, Rozenberg F, et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis. 2013;56(7):968-977. doi:10.1093\/cid\/cis1046","DOI":"10.1093\/cid\/cis1046"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Cervera C, Cofan F, Hernandez C, et al. Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis. Transpl Int. 2016;29(11):1216-1225. doi:10.1111\/tri.12848","DOI":"10.1111\/tri.12848"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Rodriguez-Espinosa D, Esforzado N, Hermida E, et al. A case of recurrent anemia due to chronic parvovirus B19 infection in a kidney transplant recipient. Can everolimus make a difference? CEN Case Rep. 2021;10(3):388-392. doi:10.1007\/s13730-021-00575-0","DOI":"10.1007\/s13730-021-00575-0"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Suzuki S, Osaka Y, Nakai I, et al. Pure red cell aplasia induced by FK506. Transplantation. 1996;61(5):831-832. doi:10.1097\/00007890-199603150-00026","DOI":"10.1097\/00007890-199603150-00026"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Misra S, Moore TB, Ament ME, Busuttil RW, McDiarmid SV. Red cell aplasia in children on tacrolimus after liver transplantation. Transplantation. 1998;65(4):575-577. doi:10.1097\/00007890-199802270-00021","DOI":"10.1097\/00007890-199802270-00021"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Yu Y, Bao R, Lyu J, Wu J, Chen J, Peng W. Foscarnet therapy for pure red cell aplasia related to human parvovirus B19 infection in kidney transplant recipients: a preliminary exploration. Infect Drug Resist. 2021;14:2911-2923. doi:10.2147\/IDR.S321936","DOI":"10.2147\/IDR.S321936"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T03:40:31Z","timestamp":1706499631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ectrx.org\/detail\/archive\/2024\/22\/1\/0\/75\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.2022.0145","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}